International consensus recommendations on the management of people with haemophilia B [PDF]
Therapeutic Advances in Hematology, 2022 Haemophilia B is a rare X-linked genetic deficiency of coagulation factor IX (FIX) that, if untreated, can cause recurrent and disabling bleeding, potentially leading to severe arthropathy and/or life-threatening haemorrhage.
Daniel P. Hart +14 more
doaj +2 more sources
Haemophilia specialist nurses’ perceptions of haemophilia B
The Journal of Haemophilia Practice, 2021 Some clinicians believe that haemophilia B is associated with less bleeding than haemophilia A, yet there appears to be little difference in health-related outcomes.
Chaplin Steve +9 more
doaj +2 more sources
Perioperative management of a patient with haemophilia B and PSVT undergoing radiofrequency ablation: A case report [PDF]
Journal of International Medical Research, 2023 Haemophilia B is a rare inherited bleeding disorder in which patients have impaired coagulation. This study describes a patient with Haemophilia B and paroxysmal supraventricular tachycardia (PSVT) who underwent radio frequency catheter ablation (RFCA ...
Yu Gan, Liping Ma, Pihua Fang
doaj +2 more sources
Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe [PDF]
Orphanet Journal of Rare Diseases, 2021 Background Real-world studies of the burden of severe haemophilia B in the context of recent therapeutic advances such as extended half-life (EHL) factor IX (FIX) products are limited.
Tom Burke +5 more
doaj +2 more sources
Eftrenonacog Alfa: A Review in Haemophilia B. [PDF]
Drugs, 2023 Eftrenonacog alfa (Alprolix®) is an extended half-life recombinant factor IX (rFIX)-Fc fusion protein (hereafter referred to as rFIXFc). Administered as an intravenous bolus, it is approved for prophylactic use and the treatment of bleeding in patients with haemophilia B in various countries worldwide, including those of the EU, as well as the USA.
Lamb YN, Hoy SM.
europepmc +3 more sources
Impact of Functional Disability on Quality of Life in Patients with Haemophilia: An Observational Study [PDF]
Journal of Clinical and Diagnostic Research, 2021 Introduction: Haemophilia is a disease characterised by multiple episodes of spontaneous as well as traumatic bleeding leading to joint pains, joint damage.
Ashish Kavi +3 more
doaj +1 more source
Gene Therapy in Hemophilia: A Transformational Patient Experience
Journal of Patient Experience, 2023 Hemophilia is a bleeding disorder caused by a single absent/defective gene and characterized by a lack of functional clotting factors. People with hemophilia may experience joint damage, pain, and psychological impairments, all of which could contribute ...
Enayet Rasul +7 more
doaj +1 more source
The B-team: Equal but different?
The Journal of Haemophilia Practice, 2021 As a person with haemophilia B, I have known there are differences between haemophilia A and haemophilia B and their respective treatment throughout my life – though I was shocked when I learnt about the impact inhibitors can have when it comes to ...
Pembroke Luke
doaj +1 more source
South African Family Practice, 2022 Background: Haemophilia A and B are X-linked recessive bleeding disorders resulting from a deficiency of factors VIII and IX, respectively. Early diagnosis and a comprehensive approach to management is mandatory.
Lethukuthula Mafisa +2 more
doaj +1 more source
Utilization evaluation of factor concentration and frequencyof bleeds among patients with haemophilia "A" and haemophilia "B" in northwest Iran [PDF]
Journal of Analytical Research in Clinical Medicine, 2013 Background Haemophilia A and B are X-linked bleeding disorders which result in decreased blood levels of coagulants. According to some studies, Hemophilia Severity Score (HSS) is higher in severe Haemophilia A(HA) than in severe Haemophilia B(HB ...
Roya Dolatkhah +5 more
doaj +1 more source